These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 8168126)

  • 1. Chronic myelomonocytic leukemia: Tel-a-kinase what Ets all about.
    Sawyers CL; Denny CT
    Cell; 1994 Apr; 77(2):171-3. PubMed ID: 8168126
    [No Abstract]   [Full Text] [Related]  

  • 2. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation.
    Golub TR; Barker GF; Lovett M; Gilliland DG
    Cell; 1994 Apr; 77(2):307-16. PubMed ID: 8168137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of the TEL gene in hematologic malignancy by diverse molecular genetic mechanisms.
    Golub TR; Barker GF; Stegmaier K; Gilliland DG
    Curr Top Microbiol Immunol; 1996; 211():279-88. PubMed ID: 8585959
    [No Abstract]   [Full Text] [Related]  

  • 4. The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways.
    Carroll M; Tomasson MH; Barker GF; Golub TR; Gilliland DG
    Proc Natl Acad Sci U S A; 1996 Dec; 93(25):14845-50. PubMed ID: 8962143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL-PDGFR beta oncoprotein.
    Jousset C; Carron C; Boureux A; Quang CT; Oury C; Dusanter-Fourt I; Charon M; Levin J; Bernard O; Ghysdael J
    EMBO J; 1997 Jan; 16(1):69-82. PubMed ID: 9009269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Signaling in leukemia: which messenger to kill?
    Pear WS
    J Clin Invest; 2000 Feb; 105(4):419-22. PubMed ID: 10683370
    [No Abstract]   [Full Text] [Related]  

  • 7. Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2).
    Ross TS; Bernard OA; Berger R; Gilliland DG
    Blood; 1998 Jun; 91(12):4419-26. PubMed ID: 9616134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for a role of NF-kappaB in the survival of hematopoietic cells mediated by interleukin 3 and the oncogenic TEL/platelet-derived growth factor receptor beta fusion protein.
    Besançon F; Atfi A; Gespach C; Cayre YE; Bourgeade MF
    Proc Natl Acad Sci U S A; 1998 Jul; 95(14):8081-6. PubMed ID: 9653143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myc is essential for transformation by TEL/platelet-derived growth factor receptor beta (PDGFRbeta).
    Bourgeade MF; Défachelles AS; Cayre YE
    Blood; 1998 May; 91(9):3333-9. PubMed ID: 9558390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [TIF1γ: a tumor suppressor gene in chronic myelomonocytic leukemia].
    Aucagne R; Droin N; Solary E; Bastie JN; Delva L
    Med Sci (Paris); 2011; 27(8-9):696-8. PubMed ID: 21880252
    [No Abstract]   [Full Text] [Related]  

  • 11. Chronic myelomonocytic leukemia patients with RAS pathway mutations show high in vitro myeloid colony formation in the absence of exogenous growth factors.
    Geissler K; Jäger E; Barna A; Alendar T; Ljubuncic E; Sliwa T; Valent P
    Leukemia; 2016 Nov; 30(11):2280-2281. PubMed ID: 27585952
    [No Abstract]   [Full Text] [Related]  

  • 12. ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemia.
    Padron E; Yoder S; Kunigal S; Mesa T; Teer JK; Al Ali N; Sekeres MA; Painter JS; Zhang L; Lancet J; Maciejewski JP; Epling-Burnette PK; Sotomayor E; Komrokji RS; List AF
    Blood; 2014 Jun; 123(23):3675-7. PubMed ID: 24904105
    [No Abstract]   [Full Text] [Related]  

  • 13. [The role of TEL and AML1 genes in the pathogenesis of hematologic malignancies].
    Zuna J
    Cas Lek Cesk; 2001 Mar; 140(5):131-7. PubMed ID: 11347199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines.
    Okuda K; Golub TR; Gilliland DG; Griffin JD
    Oncogene; 1996 Sep; 13(6):1147-52. PubMed ID: 8808688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of p21ras in hormone signalling and cell growth/transformation.
    Blackmore PF
    Adv Exp Med Biol; 1992; 321():143-6. PubMed ID: 1333165
    [No Abstract]   [Full Text] [Related]  

  • 16. [Comparison of the mode of action of ras p 21 with those of protein kinase A and C in the gene expression].
    Hori Y; Kaibuchi K; Takai Y
    Tanpakushitsu Kakusan Koso; 1991 May; 36(7):1032-6. PubMed ID: 1651531
    [No Abstract]   [Full Text] [Related]  

  • 17. JAK2 Val617Phe activating tyrosine kinase mutation in juvenile myelomonocytic leukemia.
    Tono C; Xu G; Toki T; Takahashi Y; Sasaki S; Terui K; Ito E
    Leukemia; 2005 Oct; 19(10):1843-4. PubMed ID: 16079889
    [No Abstract]   [Full Text] [Related]  

  • 18. Fusion of FIP1L1 and RARA as a result of a novel t(4;17)(q12;q21) in a case of juvenile myelomonocytic leukemia.
    Buijs A; Bruin M
    Leukemia; 2007 May; 21(5):1104-8. PubMed ID: 17301809
    [No Abstract]   [Full Text] [Related]  

  • 19. Protein tyrosine kinases and cancer.
    Kolibaba KS; Druker BJ
    Biochim Biophys Acta; 1997 Dec; 1333(3):F217-48. PubMed ID: 9426205
    [No Abstract]   [Full Text] [Related]  

  • 20. Cells transformed by ODC, c-Ha-ras and v-src exhibit MAP kinase/Erk-independent constitutive phosphorylation of Sos, Raf and c-Jun activation domain, and reduced PDGF receptor expression.
    Paasinen-Sohns A; Hölttä E
    Oncogene; 1997 Oct; 15(16):1953-66. PubMed ID: 9365242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.